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 ABSTRACT
Background: Prevalent haemodialysis (HD) patients have functional iron deficiency. Iron supplementation 
increases erythropoietic stimulating agents (ESA) responsiveness, but concern exists about overload. ESA 
responsiveness index (ERI) is currently used to quantify resistance to these agents. Frequent administra-
tion of a small dose of intravenous (i.v.) iron might improve erythropoiesis, but evidence is lacking. 
Methods: The impact of switching from a variable, intermittent dose of iron sucrose to a frequent (thrice-
-weekly) fixed dose of 10mg of iron sucrose was assessed in a sequential observational study comparing 
two periods of 4 months before and 6 months after, in 51 stable haemodialysis patients receiving main-
tenance iron and ESA (i.v. darbepoetin alfa). Results: Demographics: mean age 66.2 ± 14 years, dialysis 
vintage 55 ± 58 months, 21% Black, 43% male. Mean Hb levels (g/dL) during the baseline period (10.9 ± 
0.7) did not differ from the study period (11.05 ± 0.6), p = 0.061. Iron sucrose dose per patient/month 
was 203mg (IQR 117 -217) during baseline and 130mg during the study period (p < 0.001), and the median 
dose of ESA per patient per month decreased 22% from 90 μg to 70 μg (p < 0.001), improving ERI from 
6.17 to 4.47 (p < 0.001). While ferritin levels did not differ, mean TSAT at the end was significantly higher 
than at baseline (29.38 ± 10.8 vs. 23.76 ± 8.48 %, respectively, p < 0.001), suggesting improved availability 
of iron for erythropoiesis. Mean total monthly cost (including both i.v. iron and ESA) decreased 25%. 
Conclusion: Administration of less but more frequent iron allowed achieving target Hb, improving ESA 
response and reducing global costs.
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 INTRODUCTION
Optimizing anaemia treatment in HD patients 
remains a priority worldwide, as it has significant 
health and economic implications. As successful use 
of ESA requires sufficient available iron before and 
during therapy, almost all HD patients on ESA receive 
i.v. iron therapy1. Mobilization of iron from storage 
sites is often inadequate, and many prevalent dialysis 
patients are classified as having functional iron defi-
ciency, as they benefit from further iron administra-
tion even if storage sites are replete2,3.
It is widely considered that iron overload among 
dialysis patients was more prevalent during the pre-
-ESA era, when blood transfusion was frequent and 
i.v. iron therapy was given without concomitant ESA 
administration4 -6. Parenteral iron supplementation 
is increasing in HD patients in the US and Europe7 -9, 
following actual guidelines10 -13 that suggest increas-
ing iron to allow reduction of ESAs to treat anaemia. 
Retrospective studies have linked higher doses of 
i.v. iron administration with increased mortality and 
morbidity14 -18. Long -term randomized clinical trials 
are required to explore the effects of i.v. iron on 
outcomes in HD patients12,13,17,18. An increasing num-
ber of studies show that today, a significant propor-
tion of patients receiving iron and ESA according to 
the current guidelines have iron hepatic overload, 
as assessed by MRI19 -21.
Erythropoiesis is a continuous process where iron 
is incorporated in erythrocyte precursors when bound 
to transferrin22,23. Frequency of iron administration 
seems to be an important factor for anaemia treat-
ment optimization24 -29, as availability of iron for 
erythropoiesis might increase. Response to iron 
therapy can be measured by ESA responsiveness 
index (ERI), calculated as ESA dose (IU)/weight (kg)/
week divided by a given value of haemoglobin (Hb) 
concentration (g/dl)30.
Hepcidin is elevated in chronic kidney disease 
and blocks both the absorption of oral iron and the 
release of stored iron from reticuloendothelial mac-
rophages by degrading the iron exporter ferroportin1,22. 
 RESUMO
Introdução: A suplementação de ferro a doentes em hemodiálise (HD) com défice funcional de ferro 
aumenta a resposta aos estimuladores da eritropoiese (EE), mas existem preocupações com a possibili-
dade de sobrecarga. O índice de resposta aos estimuladores de eritropoiese (ERI) permite quantificar a 
resistência aos EE. A administração frequente de uma pequena dose de ferro endovenoso pode melhorar 
a eritropoiese, mas não existe evidência para a recomendação desta estratégia. Métodos: Avaliou -se o 
impacto no ERI da mudança de uma dose variável, intermitente, de óxido ferroso sacarosado endovenoso, 
para uma dose fixa, frequente (3 vezes por semana) de 10mg. Realizou -se um estudo observacional, 
comparativo de 2 períodos de 4 meses antes (período 1) e 6 meses depois (período 2), em 51 doentes 
estáveis, em HD sob terapêutica de manutenção com ferro endovenoso (óxido ferroso sacarosado) e EE 
(darbepoetina alfa endovenosa). Resultados: idade 66,2 ± 14 anos, vintage de diálise 55 ± 58 meses, 
21% melanodérmicos, 43% sexo masculino. A média da hemoglobina Hb (g/dL) no período 1 (10,9 ± 0,7) 
não diferiu do período 2 (11,05 ± 0,6), p = 0,061. A dose de ferro por doente/mês foi 203mg (IQR 117-
-217) durante o período 1 e 130mg no período 2 (p < 0,001). A dose mensal de EE diminuiu de 90 μg 
para 70 μg (p < 0,001), melhorando o ERI de 6,17 para 4,47 (p < 0,001). Enquanto os níveis de ferritina 
não diferiram, a média da TSAT no final foi superior à inicial (29,38 ± 10,8 vs. 23,76 ± 8,48), respectiva-
mente, p < 0,001), sugerindo melhoria da disponibilidade do ferro para a eritropoiese. A média dos custos 
mensais (incluindo o ferro e o EE) diminuiu 25%. Conclusão: A administração de menos ferro de forma 
mais frequente permitiu atingir o valor alvo de Hb, melhorando a resposta ao EE e reduzindo os custos 
globais.
Palavras -Chave: Anemia; darbepoetina alfa; ferro; hemodiálise.
Nefro - 29-3 - MIOLO.indd   214 01/10/2015   16:00:58
Port J Nephrol Hypert 2015; 29(3): 213-220    215
Improving erythropoiesis stimulating agents’ responsiveness 
in haemodialysis with less iron: an observational study
On the other hand, one of hepcidin’s production 
stimulus is iron itself23, regulated by the expression 
of two mechanisms: liver iron stores and circulating 
iron levels. Frequent administration of a small dose 
of i.v. iron could, thus, improve erythropoiesis27, 
although, at present, evidence is lacking to recom-
mend any different strategy of iron administra-
tion12,13,31. Blood losses during haemodialysis -related 
procedures can vary from 1 to 5g of elemental iron 
per year, where patient -dependent factors and centre 
practices (such as blood circuit final rinsing) are 
determinant1. Attempts to estimate the optimal dose 
of iron to match stable patients with chronic kidney 
disease stage 5 on regular HD or haemodiafiltration 
(HDF) treatment needs are challenging32,33. Safety 
concerns about excessive iron administration34, have 
led us to test the hypothesis that a smaller frequently 
administered amount of iron improves erythropoiesis 
in prevalent patients.
Our practice changed to providing frequent (thrice-
-weekly) maintenance dose of 10mg i.v. iron sucrose 
to stable patients where major blood losses are not 
evident, disregard of ferritin levels if they are between 
150 and 500 ng/mL. Those with ferritin levels between 
500 and 600ng/dL were included if TSAT was < 30%. 
This article is meant to share our results with this 
practice.
 SUBJECTS AND METHODS
This was an observational, single -centre, single-
-cohort study. The study was held in 2012 and com-
prised two time periods: 4 months before (baseline 
period) and 6 months after switch to more frequent 
iron schedule, at the fixed i.v. dose of 10mg of iron 
sucrose thrice -weekly (study period). Anaemia treat-
ment with iron sucrose during baseline period was 
determined by each nephrologist analysis of patients’ 
laboratory determinations of haemoglobin (Hb) levels 
and tendencies, taking into account ferritin and trans-
ferrin saturation (TSAT) determinations, as suggested 
by international guidelines28 -30.
Medical management did not otherwise change 
during the study period, and ESA prescription was 
adjusted monthly according to the target Hb of 
10 -13g/dL, as usual practice. Data during the baseline 
period were obtained retrospectively from the 
patients’ medical records, and subsequent data were 
collected prospectively.
 Objectives
The primary objective was to compare the impact 
on ESA responsiveness of the switch from a variable, 
intermittent dose of iron sucrose given on an less 
frequent schedule (time intervals equal to or higher 
than once weekly) to a more frequent (thrice -weekly) 
fixed dose of 10mg of iron sucrose to treat anaemia 
in a population with chronic kidney disease stage 5 
on HD/HDF treatment.
The secondary objectives were to describe the 
level of i.v. iron and ESA drugs consumption and to 
estimate anaemia drug expenditure for the two treat-
ment periods.
 Patients
Adult patients undergoing HD/HDF for more than 
6 months at the centre were included in the analysis, 
if they were under ESA (darbepoetin), had Hb levels 
between 9 and 13g/dL and ferritin between 150 and 
600 ng/mL. Those with ferritin > 500 and < 600ng/
dL were included only if TSAT was < 30%.
Exclusion criteria were: participation in other stud-
ies, known haematological disease, active oncological 
disease, recent surgery or blood transfusion (last 16 
weeks).
ESA (darbepoetin) was injected i.v. once weekly. 
Iron sucrose used was Venofer®.
 Evaluation
The Hb was assessed every month. Transferrin 
saturation (TSAT) and serum ferritin were measured 
at the beginning and the end of the study (6 months 
interval).
 Statistical analysis
Data were expressed as numbers (or percentages) 
for categorical variables, mean ± SD for continuous 
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normally distributed variables, median and inter-
-quartile range (IQR) for continuous non -normally 
distributed variables. Between -period comparisons 
were performed using paired students’ t -test for nor-
mal variables and the paired Wilcoxon test for con-
tinuous data with non -normal distribution. A p -value 
< 0.05 was considered as statistically significant.
The data were entered into a database and ana-




Of 219 patients receiving dialysis at the centre, 
57 were eligible for inclusion in the analysis and 
started a fixed dose of 10mg of i.v. iron sucrose 
thrice weekly, during dialysis. There were 53 other 
patients who were otherwise eligible but participating 
in another study. Six patients were excluded from 
the final analysis because of death (one), transplant 
(one), oncological disease requiring radiotherapy 
(three) or prolonged absence to dialysis, defined as 
> 10 days (one), leaving 51 patients. Forty -nine 
patients were on regular HDF treatment and the 
remaining were on HD. The demographics and clinical 
profile of the population are described in Table I. 
During baseline, iron sucrose administration was 
extremely variable, as it depended on each nephrolo-




Mean Hb levels (g/dL) during baseline period (10.9 
± 0.70) did not differ from the study period (11.05 
± 0.59), shown in Fig. 1, (p = 0.061).
ESA consumption and responsiveness index (ERI)
The monthly dose of darbepoetin per patient low-
ered from 90 μg(IQR 65 – 142.5) during baseline to 
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Figure 1
Mean Hb levels did not differ, as expected, since ESA’s prescription was targeting Hb between 
10 -13g/dL in both study periods.
 
Table I
Baseline demographic and clinical characteristics
Age (years) 66,2 ± 13,8 (33-95)
Gender (mal/female) 22 / 29 (43%)
Ethnicity (black/white) 11 / 40 (21% black)
Dialysis vintage (m0nths) 55,06 ± 58,4
PTHi (pg/mL) 472,7 ± 336,05
Charlson Index 6,58 ± 2,33
Primary Renal Disease 27% Diabetes / 23% Hypertension / 
21% Glomerulonephritis / 29% other 
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70 μg (IQR 46.7 – 90) during the period study (p < 
0.001), representing a 22% decrease (Fig. 2]).
According to body weight, the monthly dose of 
darbepoetin was 1,37 (IQR 0,96 – 1.37) and 1.146 
μg (IQR 0.71 - 1,47) g respectively, during baseline 
and period study (p < 0.001), representing a 17% 
decrease. As expected, ERI during the period study 
was significantly lower (4.468, IQR 3.01 -6.03) than 
baseline (6.169 IQR 4.29 -9.88, p < 0.001) (Fig. 2).
 Iron parameters
Intravenous iron consumption
The median iron sucrose dose per patient/month 
was 203.3 mg (IQR 116.7 -216.7) during baseline, 
while during the study period, the iron dose was 
fixed, totalizing 130mg/month (p < 0.001) (Fig. 3). 
This represented a decrease of 36%, which was also 
significantly different when calculated taking patient 
weight into account: 2.86 mg/Kg/month (IQR 1.95-
-3.71) vs. 1.96 (IQR 1.68 -2.18, p < 0.001).
Ferritin and transferrin saturation
Mean TSAT at the end was significantly higher 
than at baseline (29.38 ± 10.8 vs. 23.76 ± 8.48 %, 
respectively, p < 0.001) (Table II).
Mean ferritin levels did not differ during both 
treatment periods (389.3 ± 120.6 at baseline and 
385.3 ± 192.2 ng/mL at the end of the study period, 
p = 0.876).
Figure 3
The median iron sucrose dose per patient/month decreased from 203.3 to 130mg (p < 0.001).
 
Figure 2
ESA’s dose lowered 22% and ERI improved significantly during frequent low dose iron administration.
median dose of darbepoetin
μg / patient / month
ESA Responsiveness Index (ERI)
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 Economic impact
The cost of i.v. iron and ESA medications over 
time was calculated for both periods. The unit cost 
of i.v. iron (public price) at the time was 12.26 €/
ampoule (100 mg iron sucrose Venofer®) and the 
cost of darbepoetin (public price) was 1.344 €/μg. 
Results were extrapolated to obtain a yearly saving 
cost per patient by multiplying the mean monthly 
cost per patient by 12. This extrapolation is only 
indicative as unit cost estimates are centre specific, 
especially concerning darbepoetin.
The cumulative cost of i.v. iron was 24.9 €/month/
patient during baseline and 15.,9 € during the study 
period. For ESA, the mean monthly cost per patient 
was 121€ during baseline and 94 € during the study 
period. The total cost per patient from the health 
care provider’s perspective (including both i.v. iron 
and ESA) was 146 € and 110 € during baseline and 
the study period, respectively (25% decrease – Fig. 
4). The cost savings of switching from intermittent 
administration of 100mg of iron sucrose to frequent/
thrice weekly 10mg of iron sucrose for 1 year was 
estimated to be about 432€ per patient.
 DISCUSSION
The ESA resistance (ERI) is a strong, independent 
mortality risk factor in haemodialysis35 -37. In this 
population of stable HD patients, after switching to 
a fixed, frequent administration of low dose i.v. iron 
sucrose, Hb target was achieved, with a 22% reduc-
tion of absolute ESA dose/month.
A previous observational study30 has shown a 
relationship between ERI and Charlson comorbidity 
index. In this study’s population, the mean Charlson 
comorbidity index was 6.58 ± 2.33. Baseline ERI was 
already low (6.169), considering comorbidities, and 
it improved to 4.468.
In the present study, the median monthly dose 
of iron supplied during the study period was lower 
than the dose given during the baseline period to 
these patients, so these results were achieved using 
less iron. Mean ferritin levels were similar, but trans-
ferrin saturation improved, probably meaning a more 
efficient transport of available iron to the bone mar-
row. Although other studies have suggested benefit 
in providing frequent low dose maintenance i.v. iron 
to HD patients24 -29, this is, to our knowledge, the 
study with the greatest number of patients.
An improved erythropoietic response was achieved 
after switching to the dose of 10mg of iron sucrose 
thrice weekly. Other studies have found similar iron 
needs. Soluble ferric pyrophosphate delivers iron 
via dialysate slowly during dialysis treatment and 
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Figure 4
The total monthly cost of anaemia treatment (iron and ESA) per patient was 146 € and 110 € during 
baseline and the study period, respectively, a difference of 36 € (25% decrease).
 
Table II
Ferritin and TSAT at the beginning and at the end of the study
Mean ± SD Baseline Period Study Period P-value
Serum ferritin (ng/dL) 389,3 ± 120,6 385,3 ± 192,2 P = 0,876
TSAT % 23,76 ± 8,48 26,38 ± 10,8 P < 0,001 
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replaces 5 -7 mg of iron lost during each treatment 
to maintain iron balance38,39. The KDOQI guidelines 
and recommendations propose consistent IV iron 
administration at 22–65 mg per week11. Sources of 
ongoing iron loss include blood retention in the 
dialyser and tubing, that can and should be mini-
mized by good rinsing practices, whose importance 
should be emphasized. The i.v. iron infusion with 
various formulations in humans results in an early 
increase in transferrin saturation, total serum iron, 
and NTBI levels followed by an increase in ferritin 
levels several days later40 -43. However, some iron 
can bypass the RES and directly bind to transferrin41. 
In vitro studies estimate that up to 6% of i.v. iron 
bypasses RES processing43. Maybe the increased 
efficacy of frequent administration strategy is partly 
due to this mechanism. Another possible and specu-
lative explanation for the increased efficacy could 
be that the so -called “low -dose” might circumvent 
hepcidin’s increase in response to iron i.v. admin-
istration, contributing to enhanced utilization of 
given iron. Lower doses of iron therapy are welcome, 
as iron overload is known to promote endothelial 
dysfunction, cardiovascular disease, and immune 
dysfunction which are the leading causes of prema-
ture mortality in HD patients. Many studies have 
shown a strong association of ESA resistance with 
inflammation, not accomplished in this analysis, as 
it was not the focus of the present study, and for 
which a larger sample of patients would have to be 
considered.
This was an observational study, where baseline 
period was studied retrospectively. Iron administra-
tion was made according to each nephrologist’s 
usual practice during that period. As such, these 
results may not be reproducible in other clinical 
contexts. This study can be criticized as it did not 
include determination of transferrin saturation and 
ferritin levels every 3 months, as suggested by cur-
rent guidelines. Its main purpose was to evaluate 
an alternative strategy of iron administration, where 
determination of iron parameters and eventual 
changing of prescription at 3 months would be pre-
mature. Current guidelines, although prudent recom-
mending frequent evaluation of iron parameters, 
have led to a worrying increase in iron administration 
worldwide9, with notable increases in ferritin but 
not TSAT levels. With the rising cumulative i.v. iron 
doses, studies of the effects of changing i.v. iron 
dosing and other anaemia management practices 
on clinical outcomes should be a high priority9,12,13, 
and the search of alternative strategies should be 
an urgent quest. These results suggest that supply-
ing a constant, frequent, maintenance low dose of 
i.v. iron may be more adequate for the patient (since 
it may spare ESA’s and iron’s higher doses and their 
secondary effects). Concerns whether continuous 
iron supplementation leads to positive iron balance 
instead of a steady state29, can be argued against, 
as ESA’s responsiveness increased with less iron 
being supplied, suggesting that iron was used in 
erythropoiesis, not stored in deposits. Nowadays 
this question can be assessed by MRI21 to evaluate 
hepatic iron deposits in these patients, although it 
is still prohibitively expensive for use in the clinical 
practice. The economic impact of this strategy was 
welcome, as anaemia drug expenditure decreased 
by 25% in these patients.
In conclusion, in this study, although less iron 
was administered, the target Hb was achieved and 
ESA’s response improved, suggesting that adminis-
tration of low frequent doses of i.v. iron might 
improve iron’s utilization in erythropoiesis. Prospec-
tive comparative clinical trials should test this hypoth-
esis, as it may spare dialysis patients the administra-
tion of unnecessary iron, overloading stores that are 
not being efficiently used in erythropoiesis.
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